

Immune cell subset panel				
Antibody target	Clone	Fluorophore	Vendor	Catalog #
CD3	OKT3	Alexa 647	BioLegend	317312
CD4	A161A1	PE	BioLegend	357404
CD8	SK1	Alexa 700	BioLegend	344724
CD14	HCD14	BV421	BioLegend	325628
CD16	B73.1	PE-Cy7	BioLegend	360708
CD19	HIB19	PerCP-Cy5.5	BioLegend	302230
Live/dead dye		eFluor 506	Invitrogen	65-0866-14
Activation induced marker (AIM) panel				
Antibody target	Clone	Fluorophore	Vendor	Catalog #
CD4	OKT4	Alexa 488	BioLegend	317420
CD8	SK1	Alexa 700	BioLegend	344724
OX-40 (CD134)	ACT35	PE-Dazzle 594	BioLegend	350020
CD69	FN-50	PE	BioLegend	310906
4-1BB (CD137)	4B4-1	BV421	BioLegend	309820
CD14	HCD14	PerCP-Cy5.5	BioLegend	325622
CD16	B73.1	PerCP-Cy5.5	BioLegend	360712
CD19	HIB19	PerCP-Cy5.5	BioLegend	302230
Live/dead dye		eFluor 506	Invitrogen	65-0866-14
Intracellular cytokine stimulation (ICS)				
Antibody target	Clone	Fluorophore	Vendor	Catalog #
CD4	A161A1	PE	BioLegend	357404
CD8	SK1	Alexa 700	BioLegend	344724
CD14	HCD14	PerCP-Cy5.5	BioLegend	325622
CD16	B73.1	PerCP-Cy5.5	BioLegend	360712
CD19	HIB19	PerCP-Cy5.5	BioLegend	302230
IFN γ	4S.B3	Alexa 647	BioLegend	502516
TNF α	MAb11	Alexa 488	BioLegend	502915
IL-2	MQ1-17H12	BV421	BioLegend	500328
IL-4	MP4-25D2	APC-Cy7	BioLegend	500833
IL-10	JES3-9D7	PE-Dazzle 594	BioLegend	501426
Live/dead dye		eFluor 506	Invitrogen	65-0866-14
Tetramer panel				
Antibody target	Clone	Fluorophore	Vendor	Catalog #
CD8	SK1	PE-Cy7	eBioscience	25-0087-42
CD4	RPA-T4	PerCP-Cy5.5	BioLegend	300530
CD14	HCD14	PerCP-Cy5.5	BioLegend	325622
CD16	B73.1	PerCP-Cy5.5	BioLegend	360712
CD19	HIB19	PerCP-Cy5.5	BioLegend	302230
CCR7	G043H7	Alexa 488	BioLegend	353206
CD45RA	HI100	APC/Fire 750	BioLegend	304152
Streptavidin		PE	Invitrogen	S866
Streptavidin		APC	Invitrogen	S868
Streptavidin		BV421	BioLegend	405225
Streptavidin		PE-Dazzle 594	BioLegend	405247
Live/dead dye		eFluor 506	Invitrogen	65-0866-14


Supplemental Table 1. Flow cytometry panel overview. Antibodies labeled with the same fluorophore in a given panel were used to create a 'dump' channel for exclusion of the designated populations.

Tetramer panel 1			
Epitope	MHC I restriction	Fluorophore 1	Fluorophore 2
YLQPRTFLL	A*02:01	PE	APC
RLQSLQTYV	A*02:01	PE	BV421
VVFLHVTYV	A*02:01	PE	PE-Dazzle 594
SPRRARSV A	B*07:02	PE-Dazzle 594	BV421
APHGVVFL	B*07:02	PE-Dazzle 594	APC
Tetramer panel 2			
Epitope	MHC I restriction	Fluorophore 1	Fluorophore 2
KCYGVSP TK	A*03:01	PE	APC
GVYFAST EK	A*03:01	PE	BV421
GVYFAST EK	A*11:01	PE	PE-Dazzle 594
GTHWFVTQR	A*11:01	PE-Dazzle 594	BV421
RLFRKSNLK	A*11:01	PE-Dazzle 594	APC
Tetramer panel 3			
Epitope	MHC I restriction	Fluorophore 1	Fluorophore 2
KCYGVSP TK	A*03:01	PE	APC
GVYFAST EK	A*03:01	PE	BV421
LTDEMI AQY	A*01:01	PE	PE-Dazzle 594


Supplemental Table 2. Overview of pMHC I tetramer panels. The epitope, MHC I restriction, and fluorophore combinations used for the indicated tetramer panels are shown.

Sample ID	Treatment	HLA restriction for tetramer staining			Tetramer panel
HCCOV001	HC	HLA-A*11:01			2
HCCOV003	HC	HLA-A*03:01	HLA-A*11:01		2
HCCOV009	HC	HLA-A*11:01			2
HCCOV011	HC	HLA-A*02:01	HLA-B*07:02		1
HCCOV015	HC	HLA-A*02:01			1
MSCOV020	None	HLA-A*03:01			2
MSCOV027	None	HLA-A*02:01	HLA-B*07:02		1
MSCOV059	None	HLA-A*02:01			1
MSCOV070	None	HLA-A*02:01			1
MSCOV082	None	HLA-A*03:01			2
MSCOV009	GA	HLA-B*07:02			1
MSCOV047	GA	HLA-B*07:02			1
MSCOV077	GA	HLA-B*07:02	HLA-A*11:01		1 & 2
MSCOV010	DMF	HLA-A*01:01			3
MSCOV021	DMF	HLA-A*03:01			2
MSCOV035	DMF	HLA-A*03:01	HLA-A*11:01		2
MSCOV038	DMF	HLA-A*03:01	HLA-A*01:01		3
MSCOV089	DMF	HLA-B*07:02	HLA-A*03:01		1 & 2
MSCOV037	NTZ	HLA-A*03:01	HLA-A*01:01		3
MSCOV039	NTZ	HLA-A*02:01			
MSCOV052	NTZ	HLA-A*02:01	HLA-B*07:02	HLA-A*03:01	1 & 2
MSCOV057	NTZ	HLA-A*03:01			2
MSCOV069	NTZ	HLA-B*07:02			1
MSCOV016	S1P	HLA-A*02:01			1
MSCOV050	S1P	HLA-B*07:02	HLA-A*03:01		1 & 2
MSCOV060	S1P	HLA-A*02:01	HLA-B*07:02		1
MSCOV072	S1P	HLA-A*01:01			3
MSCOV012	RTX	HLA-A*01:01			3
MSCOV025	RTX	HLA-B*07:02			2
MSCOV049	RTX	HLA-A*11:01			2
MSCOV074	RTX	HLA-A*02:01			1
MSCOV076	RTX	HLA-A*03:01	HLA-A*11:01		2
MSCOV084	RTX	HLA-A*02:01			1
MSCOV014	OCR	HLA-A*11:01			2
MSCOV022	OCR	HLA-B*07:02			1
MSCOV045	OCR	HLA-B*07:02			1
MSCOV056	OCR	HLA-A*02:01			1
MSCOV058	OCR	HLA-A*03:01			2
MSCOV064	OCR	HLA-A*03:01	HLA-A*01:01		3


Supplemental Table 3. Overview of patient samples used for pMHC I tetramer analysis. HLA restriction refers to the relevant MHC I alleles used for tetramer staining. The tetramer panel refers to the panels outlined in Supplemental Table 2.



Supplemental Figure 1. Representative flow cytometry analysis for identification of immune cell subsets (A). Overview of immune cell subsets across all cohorts before and after vaccination: CD4+ T cells (B), CD8+ T cells (C), CD19+ B cells (D), CD14+ cells (E), CD14+ CD16+ cells (F), CD16+ cells (G). Comparisons of pre- and post-vaccination responses by multiple paired t-tests and comparisons of different patient cohorts by 2-way ANOVA with multiple comparisons.



Supplemental Figure 2. Analysis of vaccine-elicited spike-specific antibody responses in anti-CD20 mAb-treated MS patients. Post-vaccination net MFI of total spike IgG (**A, C**) and spike RBD IgG (**B, D**) by gender (**A-B**) and mRNA vaccine type (**C-D**), comparisons by Mann-Whitney. Net MFI of total spike IgG and spike RBD IgG versus last total IgG (**E-F**), %CD19+ B cells pre-vaccination (**G-H**), %CD19+ B cells post-vaccination (**I-J**), %CD19+ B cell change pre- vs post-vaccination (**K-L**), and interval (months) from last anti-CD20 mAb infusion to first vaccination (**M-N**), measured by simple linear regression and Spearman correlation.



Supplemental Figure 3. Gating overview for flow cytometry analysis. Representative gating strategies for AIM (A), ICS (B), and pMHC I tetramer enrichment (C). T cells were identified by live single cell lymphocytes that were dump antibody negative using the antibody panels from Supplemental Table 1. For tetramer enrichment, CD8⁺ T cells that were tetramer-positive in two fluorophores were subsequently gated on cells negative for the remaining two fluorophores to ensure specificity of tetramer binding.